PPG Industries Inc
Change company Symbol lookup
Select an option...
PPG PPG Industries Inc
DUK Duke Energy Corp
CSCO Cisco Systems Inc
HMNF HMN Financial Inc
BAM Brookfield Asset Management Inc
XOM Exxon Mobil Corp
NEWR New Relic Inc
T AT&T Inc
AICAF Air China Ltd

Materials : Chemicals | Large Cap Value
Company profile

PPG Industries, Inc. manufactures and distributes a range of coatings and specialty materials. The Company has two segments: Performance Coatings and Industrial Coatings. The Performance Coatings segment includes the refinish, aerospace, protective and marine, architectural businesses. The Industrial Coatings segment includes the automotive original equipment manufacturer (OEM), industrial coatings, packaging coatings, coatings services and specialty coatings and materials businesses. The Company's geographical segments include the United States, Canada, Western Europe, Latin America, Central and Eastern Europe, the Middle East, Africa and Asia Pacific. The Company's brands include PPG, GLIDDEN, COMEX, OLYMPIC, DULUX, SIKKENS, PPG PITTSBURGH PAINTS, MULCO, FLOOD, LIQUID NAILS, SICO, CIL, RENNER, TAUBMANS, WHITE KNIGHT, BRISTOL, HOMAX, DEKORAL, TRILAK, GORI, and BONDEX, among others.


Last Trade
0.00 (0.00%)
B/A Size

Market Hours

Closing Price
Day's Change
-1.41 (-1.16%)
B/A Size
Day's High
Day's Low

10-day average volume:

Global Pharmaceutical Pricing and Reimbursement Markets 2014-2024 - ResearchAndMarkets.com

5:26 am ET July 21, 2020 (BusinessWire) Print

The "Pharmaceutical Pricing and Reimbursement: Global Markets" report has been added to ResearchAndMarkets.com's offering.

During the first quarter of 2020, most pharmaceutical companies, such as Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Johnson & Johnson, and Novartis, witnessed a short-term boost in sales as wholesalers stockpiled products due to supply chain concerns. Some areas such as physician or hospital administered medications and travel vaccines saw a decline in sales, for obvious reasons.

Mergers and acquisitions (M&A) activity in the pharmaceutical sector keeps ticking along, with 2019 being one of the most active years in the last decade, many transactions involved the acquisition of cell and gene therapies and immune-oncology assets or to diversify risks through the adoption of digital technologies and artificial intelligence (AI).

To contain healthcare costs, governments across the globe have introduced healthcare reforms and initiated new legislation and pharmaceutical regulations that look more closely at the performance and cost-effectiveness of care. The pharmaceutical regulatory landscape is highly fragmented and divergent, and the following section summarizes the regulatory processes adopted by the latest top five European countries and the U.S. However, as regulatory oversight increases there is a growing need for regulatory harmonization.

Since the first reports of COVID-19 in Wuhan, China in December 2019, there have been 5,165,481 confirmed cases and over 336,430 confirmed deaths in 216 countries worldwide, as of May 24, 2020. Relatively few countries remain unscathed by the pandemic and scientists across the globe have worked together to advise local, regional and national healthcare organizations to contain the spread of the disease and develop prophylactic vaccinations and new therapies to treat the symptoms of the viral infection. Each country has adopted its own healthcare strategies and mobilized resources based on their individual circumstances, but only by working together will the world be able to combat this lethal disease.

More than $830 million in funding has been pledged to support R&D efforts in COVID-19, and health tech and pharmaceutical companies are working together in public-private collaborations, while numerous diagnostics, vaccines, and treatments are already under development and research.

The COVID-19 pandemic has already dramatically changed healthcare delivery, and the economic impact of COVID-19 pandemic on healthcare spending is unknown. It will depend on many factors including level and severity of infection, availability of diagnostics prophylactic treatments and vaccines, and whether the health system can manage supply constraints and defer non-essential healthcare services.

Report Scope

This new report on pricing and reimbursement in a global market provides a brief overview of the pharmaceutical markets, healthcare reforms, and regulations across the globe over the last decade and how this has impacted mergers and acquisitions and venture capitalist investment in the sector. It reviews pricing and reimbursement policies and processes in the U.S. and Europe and the ways in which pharmaceutical investment in generics, biosimilars, over the counter (OTC), small molecule and biological agents; and the shift toward more innovative medicines such as cell and gene therapies may change future treatment paradigms and future pricing and reimbursement policies.

The report includes:

An overview of the global markets for pharmaceuticals, specifically healthcare legislation and regulation, pricing mechanisms, and reimbursement procedures Analyses of the global market trends, with data corresponding to market size for 2014-2019, and projections of compound annual growth rates (CAGRs) through 2024 Information on the current price and reimbursement landscape, benchmarking statics, and future development opportunities in the pharma industry Case studies of different price and reimbursement strategies for prescription drugs, orphan drugs, generics, over-the-counter products, and value-based pricing Discussion on the impact of COVID-19 on pharmaceutical sales in Q1 2020 and overall healthcare marketplace Insight into the greater adoption of value-based pricing schemes, with emphasis on the innovative payment models, increased investment in cell and gene therapies, and long-term response to COVID-19

Key Topics Covered

Chapter 1 Introduction

Study Goals and Objectives Reasons for Doing This Study Scope of Report Information Sources Methodology Geographic Breakdown

Chapter 2 Summary and Highlights

Chapter 3 Global Healthcare Expenditures, Legislation and Pricing Mechanisms

Global Healthcare Costs Forecasts Pre-COVID Forecasts Post-COVID Acute Healthcare Response to COVID-19 Expansion of Low-Cost Digital Services Funding for COVID-19 Research and Development Drug Expenditures North America Europe Japan BRIC Economies Impact of COVID-19 on Pharmaceutical Sales in Q1 2020 Mergers and Acquisitions (M&A) M&A Activity Pre-2019 M&A Activity in 2019 M&A Activity in Q1 2020 Healthcare Reforms France Germany Italy Spain United Kingdom United States Pharmaceutical Regulation France Germany Italy Spain United Kingdom United States Acute Impact of COVID-19 on Healthcare France Germany Italy Spain United Kingdom United States

Chapter 4 Pricing Strategies

Introduction Primary Reasons for the Rise in the Cost of Pharmaceuticals Replacement of Older, Lower-Cost Drugs by Newer, Higher Priced Drugs Increased Use of Drugs New Drugs for Diseases for Which No Treatment Was Previously Available Increases in the Prices of Existing Medicines Pharmaceutical Pricing Strategies External Price Referencing Internal Referencing Pricing Prescription Drug Pricing United Kingdom United States Over-the-Counter (OTC) Drug Pricing Europe United Kingdom United States Generic Drug Pricing United Kingdom United States Orphan Drug Pricing Value-Based Pricing Open Tender Invitations and Procurement Framework Agreements

Chapter 5 Reimbursement Strategies

Pharmaceutical Reimbursement Admission to Reimbursement Reimbursement Procedure Europe United Kingdom United States Hospital Reimbursement Europe United Kingdom United States Patient Access Schemes Financially Based Schemes Outcome-Based Schemes Early Access to Medicines Schemes Europe United Kingdom United States Formulary Lists Europe United Kingdom United States Health Technology Assessments (HTA) Europe United Kingdom United States The Value of Health Economics and Outcome Research (HEOR) Top 10 HEOR Trends

Chapter 6 The Future

Greater Adoption of Value-Based Pricing Schemes Increased Investment in Cell and Gene Therapies Innovative Payment Models Greater Clarity on Brexit Political Wrangling Over Drug Prices Long-term Response to COVID-19 Undefined

Companies Mentioned

Bristol-Myers Squibb Eli Lilly GlaxoSmithKline Johnson & Johnson Novartis

For more information about this report visit https://www.researchandmarkets.com/r/2jtdm1

View source version on businesswire.com: https://www.businesswire.com/news/home/20200721005435/en/

SOURCE: Research and Markets

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.